共查询到19条相似文献，搜索用时 234 毫秒
1.
2.
3.
对保存于中国兽医微生物菌种保藏管理中心的4个不同年代(1991年4月、1996年6月、2001年1月、2006年12月)冻干的鸡传染性支气管炎病毒(IBV)M41株毒种进行了对雏鸡的毒力和病毒含量测定试验,结果表明:4个不同保存年代的IBV M41株毒种均能使雏鸡100%出现鸡传染性支气管炎典型症状,病毒含量均≥10~(6.0)EID_(50)/0.1 mL。其中一支毒种在-70℃以下保存22年11个月,其毒力和病毒含量均符合《中华人民共和国兽用生物制品规程》(二○○○年版)规定,能够满足检验需求。本试验为探寻IBV M41株毒种更加合理的保存期提供了参考。 相似文献
4.
为制备合格的鸡传染性支气管炎病毒M41株种毒,将M41株毒种接种SPF鸡胚进行传代培养,收获尿囊液、分装、冻干,并对冻干毒进行了无菌检验、支原体检验、剩余水分测定、真空度测定、外源病毒检验、病毒含量测定、特异性检验、致病性试验。结果表明,该冻干毒种各项检验均符合规定,可作为研究用种毒。本研究可为其他禽源病毒种毒的制备提供借鉴。 相似文献
5.
应用鸡传染性支气管炎病毒(H52株)与不同耐热保护剂配方和冻干曲线进行筛选.结果表明:采用冻干曲线2和耐热保护剂WXS冻干鸡传染性支气管炎病毒H52弱毒疫苗效果最佳.试制耐热活疫苗3批,其各项检验均符合要求.耐老化试验表明:经过37℃放置10d的每羽份病毒含量下降0.6～0.8个滴度,每羽份病毒含量达104.7～105.1EID50.保存期试验表明:2～8℃保存24个月疫苗每羽份病毒含量下降0.4～0.6个滴度,每羽份病毒达104.1～104.3EID50.疫苗2～8 ℃保存24个月后效检抗体水平达到1:16～1:32.免疫持续期试验表明:免疫21日龄SPF鸡,6个月后血清中和抗体效价达到1:32～1:64.田间试验表明临床观察无不良反应,安全有效.特异性试验表明耐热活疫苗抗原性不变.耐热保护剂生物学和理化特性表明保护剂安全、稳定,室温保存期达3个月. 相似文献
6.
7.
为保证制苗所用毒种质量和稳定性,在对鸡痘鹌鹑化弱毒株病毒含量、病毒纯净性、特异性、免疫原性及安全性等研究的基础上,建立了鸡痘鹌鹑化弱毒株种子批。将鸡痘鹌鹑化弱毒F278 E1(1966年6月3日冻干)通过鹌鹑连续传至4代(F282 E1)后,再经鸡胚传至14代(F282 E14)。传代毒种的鉴定结果表明：抽检的各代次的毒种均无细菌、支原体、外源病毒污染,且病毒含量检测稳定,均≥106.2EID50/0.2ml。将抽检的各代次的毒种制成活疫苗,免疫适龄鸡只后均能产生完全保护。因此,确定鸡痘鹌鹑化弱毒株基础种子代数为F282 E2～E6代,生产用毒种继代应不超过3代。种子批的建立,为鸡痘鹌鹑化弱毒株疫苗的生产奠定了基础。 相似文献
8.
为评价一株鸡传染性喉气管炎病毒流行毒株在疫苗效力评价中的应用表现，对制备的一株强毒株进行了系统鉴定，包括性状、纯净性、真空度、病毒含量、特异性等，尤其重点关注不同病毒含量对不同日龄鸡只的致病力情况。结果显示，本研究制备的鸡传染性喉气管炎病毒冻干物性状良好，无细菌、支原体和外源病毒污染，可被特异性血清完全中和，病毒含量稳定在105.1 EID50/0.2mL。该毒株致病力表现稳定，100 EID50可使80%鸡只发病或死亡，可作为一株良好的检验用强毒，为后续疫苗评价奠定基础。 相似文献
9.
鸡新城疫-鸡传染性支气管炎-禽流感-产蛋下降综合征四联灭活油乳剂疫苗的研制与免疫试验 总被引：2，自引：1，他引：2
用鸡新城疫La Sota株,鸡传染性支气管炎H120株,产蛋下降综合征127株和禽流感病毒HB1(H9N2)株做为抗原制成油乳剂灭活联苗,并对其进行了物理性状、纯净、安全性、灭活效果、保存期和免疫效力等方面的检验.证明所制备疫苗完全符合质量标准;鸡体对该疫苗4种抗原均产生了良好的免疫应答;攻毒试验证明,免疫鸡能良好地抵抗同种强毒的攻击;所制备疫苗于2～8℃保存12个月后,其免疫效力没有下降. 相似文献
10.
为研究制定猪细小病毒病冻干疫苗的保存期,将3批疫苗分别在4℃保存3、6、9和12个月,在-20℃保存6、12、18和24个月,并进行物理性状、无菌检验、安全检验和效力检验,结果证实疫苗在4℃至少可保存12个月,-20℃至少可保存24个月。 相似文献
11.
表达鸡马立克氏病病毒gB基因重组鸡痘病毒的遗传稳定性及生物安全性评价 总被引：1，自引：0，他引：1
为了评价表达鸡马立克氏病病毒gB基因重组鸡痘病毒(rFPV-gB/R)的遗传稳定性,我们将纯化后的重组病毒在CEF单层上连续传30代,引起细胞病变的速度和形态均未发生明显变化;覆盖含X-Gal的琼脂引起的空斑均为蓝色;间接免疫荧光实验证明rFPV-gB/R中的gB基因始终能稳定表达;序列测定结果表明,重组病毒在细胞上连续传30代、在SPF鸡上连续传5代后,gB基因序列没有发生任何变化;以0、10、20、30代重组病毒制成冻干疫苗进行的实验室免疫效力实验表明,细胞连续传代后rFPV-gB/R仍然保持了原有的免疫原性。可见重组鸡痘病毒gB基因的结构和免疫原性都是高度稳定的。为了评价rFPV-gB/R的生物安全性,我们将rFPV-gB/R通过SPF鸡连续传5代,检测病毒在鸡体的存在部位及其消长、生长繁殖性能和毒力变化;将rFPV-gB/R免疫鸡与未免疫鸡同笼饲养,攻击FPV-102E6强毒,以检测rFPV-gB/R感染鸡的接触传染性。结果显示,rFPV-gB/R在鸡体的存在时间大约为7d,在体内仅存在于接种部位;鸡体传代后痘病毒毒力有一定程度下降,gB基因核苷酸序列未发生任何变化;同居未免疫SPF鸡在痘病毒强毒攻击后全部发痘,可见重组病毒免疫鸡没有接触传染性,能在鸡体内稳定地传代,rFPV-gB/R具有高度的生物安全性。 相似文献
12.
采用热加速稳定性试验,以鸡胚半数致死量测定法对制备的参考疫苗进行病毒含量测定,预期其贮存有效期。根据Arrhenius方程,以不同温度下衰减速率常数K估算较低温度下K值,并计算参考疫苗在-30℃下贮存效力值下降一个滴度所需的时间约为2．4年。 相似文献
13.
The cell-associated vaccine strain CVI 988, which is the active component of several commercial Marek's disease vaccines, normally is frozen and stored in liquid nitrogen. In order to ascertain good efficacy of the vaccine, it is crucial that the right procedures are followed for thawing and diluting of the virus. In the study presented here, ampoules containing the frozen product were taken from storage in liquid nitrogen and were thawed in a water bath at 27 C, which is similar to a lukewarm bath, and in a water bath at 37 C, with and without agitation. The effect of the thawing procedure on the live virus titer of the vaccine was investigated. Samples of thawed vaccine were diluted in diluent with different temperatures, and live virus titers were determined directly after dilution and after incubation of the diluted vaccine at different temperatures. The results show that directly after thawing in the water baths at 27 C and 37 C, with or without agitation, the live virus titers for CVI 988 were all in the same range. After incubation of the thawed virus at both temperatures for 15 min, the live virus titers were still in the same range. Decreases in live virus titers were observed after incubation for 4 hr. Live virus titration of the vaccine in diluent in different temperatures revealed that the highest titers were found with diluent at a temperature of 30 C to 37 C and the lowest titers in diluent at a temperature of 5 C. In addition, a combination product containing cell-associated CVI 988 and cell-associated herpesvirus of turkeys (HVT) was tested. For this combination product, the titers for HVT also were highest in diluent with a high temperature (i.e., 37 C), whereas the titers for CVI were highest in diluent at a temperature of 22 C. Both strains had relatively low titers in diluent at 5 C. After incubation of the diluted vaccine at the various temperatures for several hours, again, live virus titrations were done. Live virus titers were most stable with diluent at temperatures of 22 C. Vaccine virus diluted in diluent at 37 C could be stabilized by placing the diluted vaccine at 5 C directly after diluting. After evaluation of these data, the following is recommended. For thawing of the vaccine, a water bath at approximately 27 C, which is similar to a lukewarm bath, is preferred. For diluting the vaccine, diluent should be used at a temperature of 22 C or higher. If diluted in diluent at temperatures higher than 22 C, the diluted vaccine should be stored under cooling in order to avoid titer losses. 相似文献
14.
Attenuated revertant serotype 1 Marek's disease viruses: safety and protective efficacy. 总被引：2，自引：0，他引：2
R L Witter 《Avian diseases》1991,35(4):877-891
In earlier studies, a revertant serotype 1 Marek's disease virus (MDV), clone Md11/75C/R2, was found to be a highly protective vaccine virus but was mildly pathogenic for susceptible chickens. The term "revertant" indicates that the virus, after attenuation, gained virulence following backpassage in chickens. The present study is an attempt to develop a more attenuated but still protective vaccine virus from Md11/75C/R2. Forty-two derivative viruses or clones from Md11/75C/R2 were evaluated. Two of these, designated clones R2/23 and R2/29, induced viremia but little or no pathology in preliminary trials and were selected for further study. In a series of nine trials, both clones provided protection against challenge with very virulent MDV strains that was superior to that induced by turkey herpesvirus (HVT) and was not significantly different (P greater than 0.05) from that induced by a bivalent (HVT + SB-1) vaccine. Both clones appeared fully attenuated based on pathogenicity tests in susceptible antibody-negative chickens. Both clones gained virulence on backpassage in chickens, but this seemed of little concern because neither virus spread by contact to other chickens. Although the two clones were very similar, clone R2/23 appeared to have a slightly lower pathogenic potential following backpassage and thus best meets the combined criteria of safety and efficacy. 相似文献
15.
为了研究最佳的H1N1亚型流感病毒鸡胚增殖参数,本试验进行了孵化前种蛋的选择与保存、鸡胚孵化中各参数设定等因素对H1N1亚型流感病毒产毒量影响的研究。其中种蛋的选择与保存,主要考察了蛋重、蛋形指数、保存期、消毒时间及方法等因素,结果显示,蛋重为55~65 g,蛋形指数为1.30~1.35,种蛋保存期为1~4 d,保存温度为16~18 ℃,保存湿度为70%~80%,保存期种蛋的甲醛熏蒸消毒时间为30 min时,可以为H1N1亚型流感疫苗生产提供最佳的种蛋。孵化过程中孵化参数对H1N1亚型流感病毒产毒量的影响,本试验主要将孵化温度、湿度、翻蛋、通风等参数作为研究对象,结果显示在生产H1N1亚型流感疫苗时,最佳孵化参数设定为:温度1~7 d为38.2 ℃、8~9 d为38.0 ℃、10 d为37.8 ℃,湿度1~10 d为65%~70%,翻蛋频率为1次/2 h,前后倾角各为45°,通风风门设定为1~5 d为4、6~10 d为5。本试验结果为H1N1亚型流感疫苗生产提供优质的鸡胚孵化技术,确保鸡胚尿囊液的质量和收获量。 相似文献
16.
In order to study the best propagation parameters of H1N1 subtype influenza virus in chicken embryo,this study was conducted to research the effects of egg selection and preservation before hatching and hatching parameters setting on production of H1N1 subtype influenza virus.In the egg selection and preservation,we mainly investigated the egg weight,egg shape index,storage period,disinfection time and method and other factors,the results showed that egg weight of 55 to 65 g,egg shape index of 1.30 to 1.35,egg storage period of 1 to 4 d,storage temperature of 16 to 18 ℃,humidity of 70% to 80%,during storage period,eggs formaldehyde fumigation time 30 min,we could provide the best eggs for H1N1 subtype influenza vaccine production.The effect of hatching parameters on production of H1N1 subtype influenza virus,this experiment mainly investigaed incubation temperature,humidity,times of turning over eggs,aeration and other parameters,the results showed that in the production of H1N1 subtype influenza virus,the optimal parameter set to hatch:temperature 1 to 7 d was 38.2 ℃,8 to 9 d was 38.0 ℃,10 d was 37.8 ℃;Humidity was 65% to 70% from 1 to 10 d;Turning over eggs frequency was 1 times/2 h,before and after each dip 45°;1 to 5 d aeration set to 4,6 to 10 d set to 5.The results provided quality chicken hatchery technology for H1N1 subtype influenza vaccine production in order to ensure the quality and yield of allantoic fluid. 相似文献
17.
以1型鸭疫里氏杆菌(RA)全基因组保守区域ompA基因的重组表达产物为包被抗原,建立了检测RA血清抗体的间接ELISA方法。原核表达的重组ompA蛋白经纯化后作为包被物,以方阵滴定法确定抗原最佳包被浓度为1.5μg/mL,待检血清最佳稀释度为1∶100。与普通的微量凝集试验相比较,该方法灵敏度高于凝集试验约16倍～128倍。与鸭源大肠埃希菌、鸭源多杀性巴氏杆菌、鸭链球菌、鸭源呼肠病毒、鸭肝炎病毒和鸭瘟病毒感染鸭血清均无交叉反应,表明该方法特异性好。利用该方法检测了雏鸭免疫RA灭活油乳剂疫苗之后血清抗体水平。 相似文献
18.
HVT-7, the standard vaccine against MD, was prepared from HVT strain FC126 grown in fibroblast cultures from SPF embryos. Ampoules of freeze dried material were prepared from a cell free suspension of virus in a solution of SPGA. The vaccine is stored at −20°C.The primary purpose of the standard vaccine was to control the variation encountered in the assay of virus content of HVT vaccines. The virus content of the standard vaccine was determined under a range of assay conditions, and the method in current use was shown to be satisfactory.A mean value for the virus content of the standard vaccine was determined using a constant assay method, by titrating 27 ampoules over a period of time. A further series of assays performed after one year's storage showed there to be no significant loss of titre.When several ampoules were titrated at the same time, some vial to vial variation was detected, but this was less than normal assay to assay variation.During routine determinations of the virus content of commercial HVT vaccines, an assay of the standard vaccine was carried out simultaneously to determine whether the assay conditions were acceptable. Assays where the value for the virus content of standard vaccine fell outside the expected range were considered invalid.The stability of the standard vaccine after reconstitution in SPGA was considered satisfactory: when reconstituted in phosphate-buffered saline, the rate of decrease in virus content was significantly greater. The vaccine could therefore be used as a control preparation in stability tests.Preliminary investigations showed that the behaviour of the standard vaccine in vivo was similar to that of satisfactory commercial vaccines, so that the preparation may also be of value in tests of vaccines for their ability to produce viraemia and confer protection. 相似文献
19.
El Garch H Minke JM Rehder J Richard S Edlund Toulemonde C Dinic S Andreoni C Audonnet JC Nordgren R Juillard V 《Veterinary immunology and immunopathology》2008,123(3-4):230-239
Successful vaccination against West Nile virus (WNV) requires induction of both neutralizing antibodies and cell-mediated immune responses. In this study, we have assessed the ability of a recombinant ALVAC-WNV vaccine (RECOMBITEK WNV) to elicit neutralizing antibodies and virus-specific cell-mediated immune responses in horses. In addition, we examined whether prior exposure to ALVAC-WNV vaccine would inhibit B and cell-mediated immune responses against the transgene product upon subsequent booster immunizations with the same vaccine. The results demonstrated that the recombinant ALVAC-WNV vaccine induced neutralizing antibodies and prM/E insert-specific IFN-gamma(+) producing cells against WNV in vaccinated horses. Prior exposure to ALVAC-WNV vaccine did not impair the ability of horses to respond to two subsequent booster injections with the same vaccine, although anti-vector-specific antibody and cell-mediated immune responses were induced in vaccinated horses. This report describes, for the first time, the induction of antigen-specific cell-mediated responses following vaccination with an ALVAC virus recombinant vaccine encoding WNV antigens. Moreover, we showed that both WNV-specific IFN-gamma producing cells and anti-WNV neutralizing antibody responses, are not inhibited by subsequent vaccinations with the same vector vaccine. 相似文献